Related Experiment Videos

The future of inflammatory bowel disease therapy

S J H van Deventer¹

¹Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands. s.j.vandeventer@amc.uva.nl

Inflammatory Bowel Diseases

|July 20, 2002

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.

Alimentary pharmacology & therapeutics·2006

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Gut·2006

Abrogation of IFN-gamma mediated epithelial barrier disruption by serine protease inhibition.

Clinical and experimental immunology·2005

Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein.

Infection and immunity·2005

Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT.

Cellular oncology : the official journal of the International Society for Cellular Oncology·2005

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.

Gut·2004

See all related articles